Introduction
============

Clinically apparent pituitary adenomas are present in about 1:1000 of the general population in Europe; the most frequent sub-types are prolactinomas, non-secreting adenomas and somatotropinomas, while Cushing's disease and thyrotropinomas are rarer ([@bib1], [@bib2], [@bib3]). Treatment of pituitary adenomas varies according to the pituitary adenoma sub-type. Responses to therapy are variable due to heterogeneity among patient profiles and tumor characteristics. For instance, acromegaly patients may be resistant to somatostatin analogs (SSA) that target the somatostatin receptor subtype 2 (SST2), while a small proportion of prolactinoma patients may not respond to labeled doses of dopamine agonists (DA). Hence, multimodal therapy involving neurosurgery, medical therapy and radiotherapy can be needed to treat pituitary adenomas ([@bib4], [@bib5], [@bib6], [@bib7]).

There is an increased likelihood of aggressive pituitary adenoma characteristics (early age at diagnosis, large tumor size, increased invasiveness) in association with a number of germline genetic mutations. Of these, the aryl hydrocarbon receptor-interacting protein (*AIP*) gene and the *MEN1* gene have been widely studied in the clinical setting. Germline *MEN1* mutations lead to multiple endocrine neoplasia type 1 (MEN1), which is characterized by tumors occurring in the parathyroids, enteropancreatic endocrine tissues and anterior pituitary ([@bib8]). *MEN1* mutations can be associated with early onset and relatively difficult-to-treat pituitary adenomas ([@bib9], [@bib10], [@bib11]). Germline *AIP* mutations (*AIP*mut) or deletions generally predispose to acromegaly, usually presenting as familial isolated pituitary adenomas (FIPA) ([@bib12]). Notably, *AIP*mut-associated somatotropinomas occur at a significantly younger age and are larger and more extensive than non-*AIP*mut acromegaly cases ([@bib13]). These characteristics lead to a high rate of gigantism among *AIP*mut-affected patients ([@bib14]). *AIP*mut-associated acromegaly patients have a significantly worse response to treatment with SST2-specific SSA compared with *AIP* wild-type acromegaly controls, both in terms of smaller IGF-1 decreases and less tumor shrinkage. In acromegaly patients without *AIP*mut, it has also been suggested that AIP immunohistochemical score in surgically-resected somatotropinomas may be a good indicator of whether patients are SST2-specific SSA responders ([@bib15], [@bib16]).

Screening studies in the general clinical population of pituitary adenomas are not particularly useful as *AIP*muts are rare (0--4% positive cases) ([@bib17], [@bib18], [@bib19]). Several recommendations have been made regarding the ideal characteristics of patients to refer for *AIP*mut testing, including pituitary gigantism patients, FIPA families, pediatric pituitary adenoma patients and those with pituitary macroadenomas (particularly acromegaly), occurring ≤30 years of age ([@bib20], [@bib21], [@bib22]). Given the characteristic resistance to SST2-specific SSA in *AIP*mut acromegaly, it has been suggested that such patients might be informative for specific screening. Oriola *et al.* reported that 8% of acromegaly patients who had failed surgery and SSA had *AIP* gene variants ([@bib23]). To address the practicality of these screening factors in the clinical setting, we analyzed *AIP* and *MEN1* status in a cohort of pituitary adenoma patients from a large regional referral population. We also assessed the relationship between tumoral immunohistochemical staining for AIP, disease characteristics and SST2-specific SSA hormonal responses in sporadic acromegaly patients.

Patients and methods
====================

This was a single-center, retrospective study performed in patients from the Department of Endocrinology, Hospital Universitario Virgen del Rocío, Seville, Spain. Patients diagnosed at any time with a pituitary adenoma were eligible, up to a cut-off date of July 2017.

Data on each patient included sex, date of birth, age at diagnosis, tumor size (maximum diameter), tumor classification (micro-or macroadenomas), treatment (surgery, medical therapy, radiotherapy) and the magnitude of hormonal responses to treatment with SSA (including % reduction in IGF-1 from baseline; GH levels on an oral glucose tolerance test), where relevant.

Inclusion criteria
------------------

We undertook a retrospective analysis of the patient population treated for pituitary adenomas who were in follow-up at the study center (*n* = 903).

We identified individuals that fell into the following categories:

1.  Somatotropinomas and prolactinomas that were hormonally resistant to medical treatment.

    Patients with documented acromegaly, defined as a failure to suppress GH following an oral glucose tolerance test, an age/sex-corrected IGF-1 level above the upper limit of the normal range and a pituitary tumor identified on magnetic resonance imaging (MRI) at baseline were assessed. Lack of hormonal control (SSA resistance) was defined as an IGF-1 above the upper limit of normal for age and sex, and a non-suppressed GH following an oral glucose load following at least 3 months of treatment with octreotide or lanreotide at their maximum labeled/tolerated dose in the pre-operative or adjuvant setting. Patients with prolactinomas had to have serum prolactin levels that were chronically elevated above the upper limit of normal in association with a macroadenoma on MRI. Lack of hormonal control (DA resistance) was defined as per Molitch ([@bib17]) as a failure to achieve normalization of serum prolactin at the highest labeled dose of cabergoline (2 mg/week). Resistance to medical therapy with SSA or DA in terms of tumor shrinkage was not included as a criterion in this study.

2.  Early-onset pituitary adenomas of any clinical sub-type.

    1.  Patients with pituitary tumors that occurred at or before 18 years of age (pediatric pituitary tumors). Pituitary tumors could be of any clinical subtype and of any diameter, as long as a tumor was confirmed on MRI at diagnosis; this subgroup also included pituitary gigantism patients.

    2.  Patients with MRI-confirmed pituitary macroadenomas that occurred (first symptoms or diagnosed) ≤30 years of age.

3.  FIPA kindreds.

    Patients that had one or more related family members with a pituitary adenoma on clinical history in the absence of MEN1 or other syndromes.

Genetic studies
---------------

Genetic analyses of the *AIP* and *MEN1* genes were performed using leukocyte-derived DNA as described previously ([@bib24]). In addition to sequence changes, all patients underwent studies to screen for exon-level or whole gene deletions or duplications using multiplex ligation-dependent probe amplification (MLPA) kit P244 (SALSA P244 Probemix, MRC-Holland) according to the manufacturer's instructions. In one patient with an *AIP* sequence variant DNA was extracted from the pituitary adenoma to test for loss of heterozygosity (LOH) at the *AIP* locus. Sequence variations were assessed and graded according to the American College for Medical Genetics guidelines. In the case where class 3 (variant of unknown significance), class 4 (likely pathogenic) and class 5 (pathogenic) sequence changes were identified, related family members underwent clinical screening for disease features and where appropriate, were offered genetic testing. Patients provided informed consent for the study, which was approved by the Ethics Committees of the CHU de Liège and the Hospital Universitario Virgen del Rocío.

Immunohistochemistry for AIP
----------------------------

We undertook a specific study of immunohistochemistry for AIP (AIP-IHC) in a series of 51 somatotropinomas operated on at the Hospital Universitario Virgen del Rocío, Seville, Spain. These 51 patients comprise part of a cohort of patients described in Venegas-Moreno *et al.* ([@bib25]). All acromegaly patients included in this study were surgically pre-treated with SSA (octreotide or lanreotide) for \>8 weeks, following the usual clinical practice in our hospital. IHC was performed using a mouse monoclonal anti-AIP antibody (1:500 dilution; NB100-127 (B35-2), Bio-Techne R&D Systems S.L.U., Madrid, Spain) as described in ([@bib16], [@bib26], [@bib27]). A semi-quantitative score for AIP staining intensity was applied: 0 = negative; 1 = weak; 2 = moderate; 3 = strong. This was multiplied by a score for expression patterning of 1 = patchy and 2 = diffuse to provide a final score ranging from 0 to 6. A low overall AIP immunostaining result was defined by a semi-quantitative AIP-IHC score ≤2, whereas high AIP-IHC was defined as a score of ≥3. For Ki-67 quantification, we counted at least 1000 cells in an area with the highest cell density. Results are expressed as the percentage of tumor cells with positive nuclei of the total number of cells. Cytokeratin CAM5.2 characteristics and staining pattern were used to classify somatotropinomas as sparsely or densely granulated tumors. The densely granulated tumors had a diffuse perinuclear CAM5.2 staining pattern in \>70% of tumor cells, while sparsely granulated adenomas had a paranuclear and spherical pattern in \>70% of cells.

Results
=======

Patient characteristics
-----------------------

As noted in [Fig. 1](#fig1){ref-type="fig"}, from a total population of 903 pituitary adenoma patients, 67 met the inclusion criteria for the genetic study and 55 of these underwent genetic testing. Details of the patient population are shown in [Table 1](#tbl1){ref-type="table"}. Among the 55 participants, there were eight FIPA families; seven were two-member families, and one was a three-member acromegaly-prolactinoma kindred. There were 12 pediatric pituitary adenoma patients, most of whom had Cushing's disease, while one had gigantism. Fifteen patients had a pituitary macroadenoma that presented ≤30 years of age, 17 patients had SSA-resistant acromegaly and three had DA-resistant prolactinomas. The median age at diagnosis of the group was 27 years (range 10--62 years) and most patients were female (*n* = 39). All but five of the patients had macroadenomas; four microadenomas occurred in children with Cushing's disease aged 12--15 years at diagnosis and one was in a FIPA patient.Figure 1Disposition of study subjects according to screening characteristics. Table 1Demographic, clinical and genetic characteristics of the study population.Patient numberTumor typeAge at disease onset (years)Tumor maximum diameter (mm)Micro or macro- adenomaSurgeryRadio- therapy*AIP* status*MEN1* status1FIPA (2-member homogeneous prolactinoma)6015MacroAdNoNoWT; MLPA normalWT; MLPA normal2FIPA (2-member homogeneous prolactinoma)1327MacroAdNonop.D172D; polymorphism; MLPA normalWT; MLPA normal3FIPA (2-member homogeneous acromegaly)3515MacroAdYesNop.D172D; polymorphism; MLPA normalWT; MLPA normal4FIPA (2-member heterogeneous TSHoma/non-functioning)176MicroAdNoNoWT; MLPA normalWT; MLPA normal5FIPA (2-member heterogeneous acromegaly/unknown type adenoma)6111MacroAdYesNoWT; MLPA normalWT; MLPA normal6FIPA (2-member homogeneous non-functioning)4626MacroAdYesNoWT; MLPA normalWT; MLPA normal7FIPA (3-member heterogeneous acromegaly/prolactinoma)1819MacroAdYesYesWT; MLPA normalWT; MLPA normal8FIPA (2-member heterogeneous prolactinoma/Cushing)2615MacroAdYesNoWT; MLPA normalWT; MLPA normal9Pediatric pituitary adenoma (non functioning)1010MacroAdNoNoWT; MLPA normalWT; MLPA normal10Pediatric pituitary adenoma (Cushing)1812MacroAdYes (2)NoWTp.R171Q (rs607969) benign/likely benign VUS; MLPA normal11Pediatric pituitary adenoma (Cushing)126MicroAdYes (2)NoWT; MLPA normalWT; MLPA normal12Pediatric pituitary adenoma (Cushing)152MicroAdYesNoWT; MLPA normalWT; MLPA normal13Pediatric pituitary adenoma (Cushing)1610MacroAdYesNoWT; MLPA normalWT; MLPA normal14Pediatric pituitary adenoma (non functioning, silent corticotrope)1615MacroAdYesNoWT; MLPA normalWT; MLPA normal15Pediatric pituitary adenoma (Cushing)1025MacroAdYes (2)NoWT; MLPA normalWT; MLPA normal16Pediatric pituitary adenoma (Cushing)113MicroAdYesNoWT; MLPA normalWT; MLPA normal17Pediatric pituitary adenoma (Cushing)155MicroAdNoNoWT; MLPA normalWT; MLPA normal18Pediatric pituitary adenoma (Cushing)1511MacroAdYesNop.D44D; polymorphism; MLPA normalWT; MLPA normal19Pediatric Pituitary adenoma (non functioning, silent corticotrope)1737MacroAdYes (4)Yesp.A299V (c.896 C\>T) AIP; likely benign VUS; No LOH in tumor; MLPA normalWT; MLPA normal20Pediatric pituitary adenoma (gigantism)1223MacroAdYesNoWT; MLPA normalWT; MLPA normal21Acromegaly, resistant to SSA3715MacroAdYesYesWT; MLPA normalWT; MLPA normal22Acromegaly, resistant to SSA4025MacroAdYesYesWT; MLPA normalWT; MLPA normal23Acromegaly, resistant to SSA3912MacroAdYesYesWT; MLPA normalWT; MLPA normal24Acromegaly, resistant to SSA5815MacroAdYesNoWT; MLPA normalWT; MLPA normal25Acromegaly, resistant to SSA2530MacroAdYesYesWT; MLPA normalWT; MLPA normal26Acromegaly, resistant to SSA4737MacroAdYesYesWT; MLPA normalWT; MLPA normal27Acromegaly, resistant to SSA6218MacroAdYesYesWT; MLPA normalWT; MLPA normal28Acromegaly, resistant to SSA4150MacroAdYesYesWT; MLPA normalWT; MLPA normal29Acromegaly, resistant to SSA6020MacroAdYesNoWT; MLPA normalWT; MLPA normal30Acromegaly, resistant to SSA5818MacroAdYesNoWT; MLPA normalWT; MLPA normal31Acromegaly, resistant to SSA4140MacroAdYesYesWT; MLPA normalWT; MLPA normal32Acromegaly, resistant to SSA4220MacroAdYesNoWT; MLPA normalWT; MLPA normal33Acromegaly, resistant to SSA2522MacroAdYes (2)YesWT; MLPA normalWT; MLPA normal34Acromegaly, resistant to SSA3138MacroAdYes (2)YesWT; MLPA normalWT; MLPA normal35Acromegaly, resistant to SSA4070MacroAdYes (2)YesWT; MLPA normalWT; MLPA normal36Acromegaly, resistant to SSA4037MacroAdYesYesWT; MLPA normalWT; MLPA normal37Acromegaly, resistant to SSA2025MacroAdYesNoWT; MLPA normalWT; MLPA normal38Prolactinoma, resistant to DA3240MacroAdYesNoWT; MLPA normalWT; MLPA normal39Prolactinoma, resistant to DA3427MacroAdYesYesWT; MLPA normalWT; MLPA normal40Prolactinoma, resistant to DA5030MacroAdYesNoWT; MLPA normalWT; MLPA normal41Sporadic macroadenoma onset ≤30 years (acromegaly)2823MacroAdYesYesWT; MLPA normalWT; MLPA normal42Sporadic macroadenoma onset ≤30 years (non functioning; silent corticotrope)2320MacroAdYesNop.D172D; polymorphism; MLPA normalWT; MLPA normal43Sporadic macroadenoma onset ≤30 years (non functioning)2830MacroAdYesNoWT; MLPA normalWT; MLPA normal44Sporadic macroadenoma onset ≤30 years (acromegaly)2825MacroAdYesYesWT; MLPA normalWT; MLPA normal45Sporadic macroadenoma onset ≤30 years (non functioning; silent corticotrope)2525MacroAdYes (3)NoWT; MLPA normalWT; MLPA normal46Sporadic macroadenoma onset ≤30 years (non functioning)2822MacroAdYesNoWT; MLPA normalWT; MLPA normal47Sporadic macroadenoma onset ≤30 years (prolactinoma)2713MacroAdYesNoWT; MLPA normalWT; MLPA normal48Sporadic macroadenoma onset ≤30 years (non functioning)2342MacroAdYes (2)NoWT; MLPA normalWT; MLPA normal49Sporadic macroadenoma onset ≤30 years (non functioning)2230MacroAdYes (3)YesWT; MLPA normalWT; MLPA normal50Sporadic macroadenoma onset ≤30 years (acromegaly)2420MacroAdYesNoWT; MLPA normalWT; MLPA normal51Sporadic macroadenoma onset ≤30 years (prolactinoma)3030MacroAdYesNoWT; MLPA normalWT; MLPA normal52Sporadic macroadenoma onset ≤30 years (prolactinoma)2311MacroAdYes (2)NoWT; MLPA normalWT; MLPA normal53Sporadic macroadenoma onset ≤30 years (Acromegaly)3030MacroAdYes (3)YesWT; MLPA normalWT; MLPA normal54Sporadic macroadenoma onset ≤30 years (prolactinoma)1940MacroAdYes (2)YesWT; MLPA normalWT; MLPA normal55Sporadic macroadenoma onset ≤30 years (prolactinoma)1633MacroAdYes (2)YesWT; MLPA normalWT; MLPA normal[^3]

Genetic results
---------------

The screening study was undertaken to assess whether patients with the screening criteria had *AIP* and *MEN1* mutations/deletions, but no pathological genetic variants were found in *AIP* or *MEN1* in any of the 55 patients. Similarly, on MLPA, no deletions of *AIP* or *MEN1* or their individual exons were found. Three subjects were heterozygous for the p.D172D *AIP* variant (rs2276020), and one had the p.D44D variant (rs11822907); both variants are considered benign or likely benign in nature. One patient had the p.A299V (rs148986773) change in *AIP*, which has been reported previously in clinical studies. It is considered more likely to be benign, and based on tumor DNA studies, we confirmed that there was no loss of heterozygosity (LOH) at the *AIP* locus, which further supports this non-pathological classification. Family screening demonstrated the p.A299V change in an asymptomatic parent and in a sibling. There was one *MEN1* variant found in one pediatric patient with Cushing's disease, p.R171Q (rs607969), although this too is considered as benign/likely benign.

Immunohistochemistry of AIP in sporadic acromegaly
--------------------------------------------------

A total of 51 somatotropinomas from sporadic acromegaly patients were analyzed. These patients were not selected according to tumoral or other disease characteristics and their baseline clinical features are shown in [Table 2](#tbl2){ref-type="table"}. Forty-five tumors were macroadenomas. Nine of the adenomas displayed both GH and prolactin expression while the remaining 42 were purely GH-secreting tumors. Representative images of AIP immunohistochemistry in normal pituitary and in somatotropinomas with different semiquantitative AIP-IHC scores are shown in [Fig. 2](#fig2){ref-type="fig"}. All somatotropinomas displayed some degree of AIP immunoreactivity. Thus, none of the patients were classified as score 0. Twenty-four somatotropinomas exhibited low AIP-IHC scores (≤2). Tumor size was significantly greater in the low AIP-IHC group (median = 25 mm (IQR, 15--35.8)) as compared with the high AIP-IHC patients (median = 15 mm (IQR, 10--20.3); *P* = 0.002). No other statistically significant differences in gender, age and GH or IGF-1 levels at diagnosis were observed between low and high AIP-IHC patient groups ([Table 2](#tbl2){ref-type="table"}).Figure 2Immunohistochemical detection of AIP in somatotropinomas. Representative images of AIP immunohistochemistry in normal pituitary (A) and GH-secreting adenomas showing low (B; diffuse, weak) and high AIP expression (C; patchy, strong). Scale bar: 50 μm in C for A and B. (D) Comparison of IGF-1 percent reduction after 3 months of SSA treatment in tumors with low or high AIP-IHC expression. (E) Comparison of IGF-1 percent reduction after 6 months of SSA treatment with low or high AIP-IHC expression. Data points represent values for each individual patient. Mean and standard error ([s.e.m.]{.smallcaps}) values are shown. Table 2Baseline characteristics of 51 acromegaly patients studied using AIP immunohistochemistry.CharacteristicsLow AIP-IHCHigh AIP-IHC*P*-ValueSex (number, male/female)11/13M15/120.488Age at diagnosis (years, median, IQR)37 (32.5--42.5)40 (31--48)0.515Maximum tumor diameter at diagnosis (mm, median, IQR)25 (15--35.8)15 (10--22.3)**0.002**GH at diagnosis (ng/mL, median, IQR)20.5 (9.9--44.3)22.5 (8.4--40)0.852IGF-1 at diagnosis (%ULN, median, IQR)280 (238--343)228 (182--311)0.163Treatment duration (months, median, IQR)6 (2--10.5)5.5 (2.8--11.5)0.718Ki-67 index (%, median, IQR)0.4 (0.3--1)0.2 (0.1--1)0.143GH-producing histological subtypes (number, sparsely/densely granulated)12/79/18**0.046**[^4][^5]

Data to determine the response to SSA was available for 39 patients at 3 months of treatment (26 before surgery and 13 as adjuvant therapy) and for 35 patients at 6 months of treatment (18 before surgery and 17 as adjuvant therapy). As there were no differences in the magnitudes of response to SSA between patients treated preoperatively or adjuvantly ([@bib25]), we analyzed all of the SSA response data as a group at 3 months and then at 6 months. No differences in the percentage reduction in IGF-1 were observed between the low and high AIP-IHC groups after either 3 or 6 months of SSA treatment ([Fig. 2](#fig2){ref-type="fig"}).

Discussion
==========

In this study, we assessed the prevalence of germline mutations of *AIP* and *MEN1* in a focused group of 55 patients with familial and sporadic isolated pituitary adenomas from a large tertiary referral center in Seville, Spain. The group was selected based on suggested criteria for patients that had a potential for having *AIP* and *MEN1* mutations. The study cohort was young overall (median age 27 years) with large pituitary adenomas (median maximum diameter 22 mm) and included eight new FIPA families with 2--3 affected members. None of the 55 patients had germline mutations in *AIP* or *MEN1* and no cases of *AIP*/*MEN1* deletions were found.

The results of the current study, while at first glance 'negative', do provide important new and confirmatory information. When individual clinical centers are considering screening programs for pituitary adenoma patients, the relative importance of different proposed criteria need to be weighed. As in the current study, many new FIPA families can be identified at large tertiary referral centers, once the family history is specifically explored. Most such kindreds will be *AIP*mut negative, as about 80% of FIPA families remain genetically unexplained. Pediatric pituitary adenoma series report *AIP*mut rates of 11--20% ([@bib28], [@bib29], [@bib30], [@bib31]). Most pediatric *AIP*mut-related pituitary adenomas are somatotropinomas with occasional prolactinomas or non-functioning tumors. Our pediatric cohort showed no *AIP*mut, which is probably because most had Cushing's disease, which confirms our previous findings that Cushing's disease is only very rarely associated with pathological *AIP*mut ([@bib29]). This study underlines that *AIP*mut testing in pediatric patients with Cushing's disease has a low likelihood of being positive. In pediatric and adolescent patients with *AIP*mut-related pituitary adenomas, a typical presentation is with pituitary gigantism. Indeed, *AIP*mut are the single most important cause of pituitary gigantism, explaining 29% of cases, followed by X-linked acrogigantism (X-LAG) syndrome (10%) and McCune Albright syndrome (5%) ([@bib14]). In the current cohort there was only one young patient with pituitary gigantism and he was negative for not only *AIP*/*MEN1* mutations but also did not have X-LAG syndrome on array comparative genome hybridization (data not shown).

There is considerable uncertainty about how to best define 'young-onset' adult pituitary adenoma, with age cutoffs of 30 and 40 years having been proposed in the past ([@bib19], [@bib30], [@bib31]). While Preda *et al.* found a low rate (approximately 3%) of *AIP*mut in a prospective, single-center study of patients aged \<40 years, we reported a higher rate of nearly 12% among an international group of sporadic macroadenoma patients aged \<30 years at diagnosis ([@bib19], [@bib30]). The contrast between the current results and those of our previous multicenter study may be explained by the relatively more severe patient profile of the *AIP*mut-positive patients identified in our previous study ([@bib30]). While in the Seville sporadic cohort the median age was 27 years and the median tumor diameter was 23 mm, in our international study the median age at diagnosis (18 years) and maximal tumor diameter (39 mm) were indicative of more severe disease. It may be that in order to optimize screening, the age of adult patients should be revised downward to well below 30 years at disease onset/diagnosis and that only patients with extensive and/or invasive macroadenomas should initially be considered for *AIP*mut analysis.

The topic of standardized screening criteria for *AIP* mutations was considered recently by Caimari *et al.* ([@bib32]). They devised a risk stratification assessment for genetic screening that confirmed a number of factors such as young age at onset (including gigantism), FIPA, macroadenomas and GH excess (all *P* ≤ 0.001). Young age at onset (19--30 years) alone was also an independent risk factor (*P* = 0.015). This stratification system points to certain very high-risk categories such as FIPA cases with macroadenomas occurring up to 18 years of age. In the absence of either FIPA, a macroadenoma or an age up to 18 years, the risk fell markedly in that stratification system. In the case where only moderate risk of an *AIP*mut is present, individual patient characteristics become important. In such instances, it is vital to take an individualized approach so as not to discount aggressive cases of large prolactinomas, non-functioning adenomas or apoplexy cases. No general risk stratification is foolproof, as shown by our current study: despite meeting the criteria for risk of *AIP*mut like the eight FIPA kindreds, no *AIP*mut cases were seen. Expectations about the likelihood of identifying mutation positive cases in a hospital cohort must take into account the underlying frequency from large collaborative datasets (e.g. only 20% of FIPA kindreds are AIPmut positive).

This study addressed whether adding the criteria of resistance to medical therapy with first-generation SSA in acromegaly patients, or maximum labeled dose cabergoline in prolactinoma patients could improve the identification of *AIP* or *MEN1* mutations. Resistance to first-generation SSA is an established characteristic of *AIP*mut*-*related acromegaly ([@bib13]). This may be caused by interference with important mediators of SST2 function, such as Gai2 or ZAC1 ([@bib33], [@bib34]). Oriola *et al.* previously reported a separate Spanish cohort of acromegaly patients with SSA resistance and noted a rate of *AIP*mut approaching 8% ([@bib23]). The current study suggests that even in a population of acromegaly patients with macroadenomas, the addition of resistance to octreotide and lanreotide does not improve detection rates for *AIP* or*MEN1* mutations. Given the identification of cabergoline-resistant prolactinoma patients with *AIP* and *MEN1* mutations in previous international studies ([@bib10], [@bib13], [@bib35]), we also screened for this criterion in the Seville population but only three patients were identified and none carried an *AIP* or *MEN1* mutation/deletion.

Previous studies have reported that decreased tumoral AIP expression might be associated with poor response to first-generation SSA treatment of somatotropinomas, although results are inconsistent ([@bib15], [@bib16], [@bib26], [@bib33], [@bib36]). We did not find any such relationship between AIP IHC and response to SSA treatment using the same commercial AIP antibody and scoring system as in those previous studies. A possible explanation for the discrepancy is that all the acromegaly patients included in our IHC study received SSA pre-treatment while waiting for surgery. Pre-treatment with octreotide/lanreotide in acromegaly is associated with increased AIP protein expression ([@bib26], [@bib33]). Chahal *et al.* did not find an overall correlation between SSA response and AIP IHC in pretreated patients ([@bib33]). Jaffrain-Rea *et al.* reported significantly higher pre-operative GH and IGF-1 levels in a group of 67 acromegaly patients with low tumoral AIP staining; this difference was, however, not seen among a subgroup (*n* = 25) of patients who had not received preoperative SSA treatment ([@bib26]). Furthermore, the only significant differences between low and high AIP IHC staining in non-SSA pretreated acromegaly patients in that study were in terms of increased invasiveness and suprasellar extension associated with low AIP staining. These inter-study differences reflect an imperfect correlation between AIP IHC and hormonal SSA responses. It should be noted that AIP IHC is quite variable in somatotropinomas, even among populations with germline *AIP*mut and is a poor tool for screening for possible *AIP*mut cases in a pathological setting ([@bib36]). Given the fact that AIP-IHC results could be biased or influenced by SSA pretreatment, as noted earlier, studies with well-balanced groups of SSA pretreated and non-pretreated acromegaly patients would be helpful to clarify the role of the effect of SSA pretreatment on AIP-IHC. Subsequent studies could also explore the role of AIP-IHC in predicting control of acromegaly with SSA under combined hormonal and tumor shrinkage criteria.

More consistently than predicting hormonal effects in acromegaly, low AIP IHC does seem to correlate with tumor aggressiveness, invasion and extension in somatotropinomas ([@bib16], [@bib26]). This echoes our finding of significantly larger tumor size in low vs high AIP-IHC acromegaly groups. We also found that sparsely granulated adenomas were significantly more frequent in the low AIP-IHC group. Sparsely granulated adenomas have previously been shown to be associated with lower responses to octreotide/lanreotide and better responses to pasireotide and they predominate in *AIP*mut cases ([@bib27], [@bib37], [@bib38]). In sporadic acromegaly, it is difficult to know whether the relationship between low AIP-IHC and more frequent sparsely granulated tumors is a cause or an effect. Specific studies to fully explain the means by which *AIP*mut cause somatotrope tumorigenesis will hopefully cast some light on this issue.

In conclusion, our understanding of the genetics of pituitary adenomas is expanding quickly and many targets for screening are emerging. Due to this rapid progress, it is difficult to devise concrete guidelines for genetic testing in pituitary adenoma populations, although both expert recommendations and risk stratification models are helpful. While many pituitary adenoma patients with *AIP* and *MEN1* mutations have been reported in the literature, the current study underlines that in the majority of FIPA and sporadic cases, no genetic cause is known. Furthermore, SSA resistance did not help to identify groups of patients with *AIP* and *MEN1* mutations in this study. AIP-IHC is a promising pathological marker for somatotropinoma growth and invasion, although this study suggests that its role in predicting hormonal responses to SSA in acromegaly appears to be limited. Improved focus on patients with large and aggressive macroadenomas in the setting of pituitary gigantism, FIPA and pediatric-onset patients (apart from Cushing's disease) may help to refine genetic testing protocols. Nonetheless, other novel genetic factors in pituitary tumorigenesis remain to be identified.
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